U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07363252) titled 'Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients' on Dec. 10, 2025.
Brief Summary: Retrospective-prospective observational multicentric study including radically resected EGFR-mutated NSCLC patients relapsed during or after adjuvant osimertinib, received according to clinical practice
Study Start Date: Jan., 2026
Study Type: OBSERVATIONAL
Condition:
EGFR-mutated NSCLC
Intervention:
DRUG: Osimertinib
Characterization of the molecular mechanisms of recurrence to adjuvant osimertinib
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Gruppo Oncologico Italiano di Ric...